Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal recessive congenital ichthyosis in which the cause of the disease is a mutation in the TGM1 gene.
Features include always present findings: Dry, scaly skin (ichthyosis); and very common findings: Ectropion, Palmoplantar hyperkeratosis, and Congenital nonbullous ichthyosiform erythroderma. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 8 | Desquamation of skin soon after birth, Alopecia, Nail dysplasia |
Pregnancy and birth | 2 | Congenital ichthyosiform erythroderma, Congenital nonbullous ichthyosiform erythroderma |
Head and neck | 1 | Everted lower lip vermilion |
Muscles | 1 | Flexion contracture |
Age of onset: at birth.
TGM1 function has not been fully characterized.
Autosomal recessive congenital ichthyosis 1 is associated with mutations in the TGM1 gene on chromosome 14.
Genetic testing for TGM1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for autosomal recessive congenital ichthyosis 1 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 3 very common features, 2 common features.
No clinical trials have been registered for autosomal recessive congenital ichthyosis 1.
40 publications have been identified in PubMed for autosomal recessive congenital ichthyosis 1. Research spans Case Report / Case Series (48%), Basic Science / Preclinical (15%), and Gene Therapy / Novel Therapeutics (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 19 | 48% |
Laboratory research | 6 | 15% |
New treatment approaches | 6 | 15% |
Disease patterns and progression | 5 | 13% |
Research summaries | 3 | 8% |
Testing and diagnosis research | 1 | 3% |
Elgie T (2026). [PMID: 42001132](https://pubmed.ncbi.nlm.nih.gov/42001132/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Asahi Y (2026). [PMID: 41791722](https://pubmed.ncbi.nlm.nih.gov/41791722/). *Anesthesia progress*. [Basic Science / Preclinical]
Apaydin DC (2026). [PMID: 41605220](https://pubmed.ncbi.nlm.nih.gov/41605220/). *Cell stem cell*. [Gene Therapy / Novel Therapeutics]
Palanki R (2026). [PMID: 41650933](https://pubmed.ncbi.nlm.nih.gov/41650933/). *Cell stem cell*. [Case Report / Case Series]
Swaroop S (2026). [PMID: 41769439](https://pubmed.ncbi.nlm.nih.gov/41769439/). *Cureus*. [Case Report / Case Series]
Tajiri M (2026). [PMID: 41220238](https://pubmed.ncbi.nlm.nih.gov/41220238/). *J Dermatol*. [Case Report / Case Series]
Kumar A (2026). [PMID: 41949191](https://pubmed.ncbi.nlm.nih.gov/41949191/). *Indian J Dermatol Venereol Leprol*. [Epidemiology / Natural History]
Jiang X (2026). [PMID: 41530952](https://pubmed.ncbi.nlm.nih.gov/41530952/). *Br J Dermatol*. [Case Report / Case Series]
Hayashi M (2026). [PMID: 42145896](https://pubmed.ncbi.nlm.nih.gov/42145896/). *Case Rep Dermatol*. [Case Report / Case Series]
Sattar MA (2026). [PMID: 42196615](https://pubmed.ncbi.nlm.nih.gov/42196615/). *Int J Mol Sci*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:58 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center